Medifast (NYSE:MED) Issues Quarterly Earnings Results

Medifast (NYSE:MED) issued its earnings results on Tuesday. The specialty retailer reported ($0.55) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.21, Zacks reports. The firm had revenue of $75.10 million during the quarter, compared to analyst estimates of $71.40 million. Medifast had a negative net margin of 4.84% and a negative return on equity of 4.19%. Medifast updated its FY 2026 guidance to -2.750–1.55 EPS and its Q1 2026 guidance to -0.700–0.15 EPS.

Here are the key takeaways from Medifast’s conference call:

• CEO Dan Chard will step down as CEO effective June 1, 2026 and remain chairman, with President Nick Johnson expected to assume the CEO role — the company describes this as a planned, internal succession.
• Medifast is repositioning as a metabolic health company centered on its “Metabolic Synchronization” science, citing a 16-week study showing a 14% reduction in visceral fat and 98% preservation of lean mass, and plans a new product line targeted for launch in Q4 2026.
• Early operational signs include coach productivity turning positive (revenue per active earning coach +6% YoY, highest since Q3 2024) and increased coach-led meetings and referrals; management expects these trends to drive future client acquisition and coach growth.
• Near-term financials remain pressured: Q4 revenue fell 36.9% to $75.1M and active earning coaches declined 40.6% (to ~16,100), producing a Q4 net loss of $18.1M ($1.65 per share) that included a $12.1M non‑cash deferred tax valuation allowance, though the company ended the year with $167.3M cash and no debt and announced >$30M of targeted cost savings.

Medifast Price Performance

Shares of NYSE:MED opened at $10.71 on Thursday. The firm has a fifty day moving average price of $11.33 and a two-hundred day moving average price of $12.31. The company has a market cap of $117.69 million, a price-to-earnings ratio of -6.26 and a beta of 0.53. Medifast has a one year low of $10.10 and a one year high of $15.95.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Stephens cut their price objective on shares of Medifast from $15.00 to $12.00 and set an “equal weight” rating for the company in a report on Thursday. Weiss Ratings restated a “sell (d)” rating on shares of Medifast in a research report on Thursday, January 22nd. Finally, Wall Street Zen raised Medifast from a “sell” rating to a “hold” rating in a report on Saturday, December 6th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and a consensus target price of $12.00.

Institutional Investors Weigh In On Medifast

Large investors have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. increased its stake in Medifast by 30.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 776,829 shares of the specialty retailer’s stock worth $8,297,000 after acquiring an additional 181,618 shares during the last quarter. Bank of America Corp DE boosted its position in shares of Medifast by 14.2% during the 3rd quarter. Bank of America Corp DE now owns 452,543 shares of the specialty retailer’s stock valued at $6,186,000 after acquiring an additional 56,174 shares during the last quarter. Lido Advisors LLC purchased a new position in shares of Medifast during the third quarter worth about $4,521,000. Dimensional Fund Advisors LP grew its holdings in shares of Medifast by 9.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 326,240 shares of the specialty retailer’s stock worth $3,484,000 after purchasing an additional 27,871 shares in the last quarter. Finally, Steamboat Capital Partners LLC bought a new position in shares of Medifast in the fourth quarter worth approximately $2,952,000. Institutional investors own 95.51% of the company’s stock.

Medifast Company Profile

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.